Industry Partner Update: PepGen

Upcoming webinar: Wednesday, April 10 from 10AM – 11AM ET.

Join the latest webinar from PepGen, as they discuss the latest information about PGN-EDO51, the company’s lead product candidate for the treatment of people living with Duchenne muscular dystrophy whose mutations are amenable to exon 51 skipping, as well as details on their upcoming studies, including CONNECT1 in Canada.

Submit Your Questions

Have questions for our researchers during this upcoming webinar? Complete the form and they will be asked during the information session. 

Note that you do not need to enter your name or your email if you wish to remain anonymous. Your question will still be asked. 

If you cannot attend the live webinar, watch the recording and get the answers to your questions.